{
  "trial_id": "NCT02227264",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "participate in the study",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Visit 2: Informed consent is signed",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Test panel of self rating scales (Quality of Life Questionnaire-Core 30 (QLQ-C30), Positive States of Mind (PSOM )and Hospital Anxiety and Depression scale (HAD), cognitive test (Montreal cognitive assessment (MoCA-Test)) and muscle strength (Timed stand test).",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Blood samples are drawn within 2 weeks before and analyzed for: parathyroid hormone (p-PTH), s-ionized calcium, p-total calcium, p-albumin, p-creatinine, p-phosphate, s-25-OH-D-vitamin and p-TSH.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Initiation of treatment with Mimpara\u00ae 30 mg x 1.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Clinical examination (general condition, blood pressure). For fertile women, a pregnancy test is demanded before enrollment.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Visit 3: Week 1 (\u00b1 2 days); blood samples for analysis of ionized calcium. History of symptoms related to hypocalcemia (paresthesias, cramps, muscle fatigue). Clinical examination when indicated (general condition, blood pressure).",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Visit 4: Week 2 (\u00b1 2 days); blood samples for analysis of ionized calcium. History as above.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Mimpara\u00ae continued, If the ionized calcium level is >1.33 mmol/l: increase of dosage of Mimpara\u00ae to 30 mg x 2.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Visit 5: Week 3 (\u00b1 2 days); blood samples for analysis of ionized calcium. History as above.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Mimpara\u00ae treatment completed.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Visit 6 (3): Week 4 (\u00b1 2 weeks in study B); Test panel of self rating scales (QLQ-C30, PSOM and HAD), cognitive test (MoCA-Test) and muscle strength (Timed stand test). Blood samples are drawn and analyzed for: plasma (p)-PTH, serum(s)-ionized serum calcium, p-total calcium, p-albumin, p-creatinine, p-phosphate.",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnancy",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Breast feeding",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Fertile woman not using contraceptives (IUD or pills)",
      "label": "triggers",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has metastatic papillary thyroid cancer and is scheduled for parathyroid surgery, which may trigger exclusion criterion 'Scheduled for parathyroid surgery'. However, this is not explicitly stated as an exclusion criterion in the study model. Therefore, overall assessment remains likely eligible.",
  "_meta": {
    "topic_id": "11",
    "trial_id": "NCT02227264",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}